Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
| ▸ | GLP1R | P43220 | 1/20 | 0.37 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.37 |
| ▸ | RAMP3 | O60896 | 5/20 | 0.37 |
| ▸ | CALCR | P30988 | 5/20 | 0.37 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.37 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.37 |
| ▸ | RXFP4 | Q8TDU9 | 1/20 | 0.37 |
| ▸ | RXFP3 | Q9NSD7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13723956 | 0.95 | PRMT1 (0.40) | PRMT1ECE1GLP1RMUS81RAMP3 | |
| SCHEMBL14404788 | 0.95 | PRMT1 (0.40) | PRMT1ECE1GLP1RMUS81RAMP3 | |
| SCHEMBL13723861 | 0.94 | RXFP4 (0.40) | PRMT1ECE1GLP1RMUS81PTH1R | |
| SCHEMBL14404798 | 0.94 | RXFP4 (0.40) | PRMT1ECE1GLP1RMUS81PTH1R | |
| SCHEMBL16323036 | 0.93 | PRMT1 (0.38) | PRMT1ECE1GLP1RMUS81 | |
| SCHEMBL2367849 | 0.93 | PRMT1 (0.39) | PRMT1ECE1GLP1RMUS81RAMP3 | |
| SCHEMBL14404950 | 0.93 | PRMT1 (0.39) | PRMT1ECE1GLP1RMUS81RAMP3 | |
| SCHEMBL2367841 | 0.93 | PRMT1 (0.39) | PRMT1ECE1GLP1RMUS81RAMP3 | |
| SCHEMBL13723352 | 0.91 | OPRM1 (0.44) | RAMP3CALCR | |
| SCHEMBL13723037 | 0.91 | OPRM1 (0.44) | ECE1GLP1RMUS81RAMP3CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | PRMT1 3756/4885ECE1 3037/4885GLP1R 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.